Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced its participation in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Sabrina Martucci Johnson will speak on the ARPA-H | Investing in Women's Health panel on Tuesday, January 14th at 2:15 p.m. PT.

The conference features three panels dedicated to women's health, highlighting the growing focus on innovation in this sector. This follows Daré's recent collaboration with ARPA-H in ringing the Nasdaq closing bell on January 2nd.

The company is developing potentially disruptive therapeutic candidates in areas including contraception, sexual health, menopause, infectious disease, fertility, and pelvic pain. Johnson will also speak at a Grant Engine event on January 15th about non-dilutive funding, highlighting two recent $10 million awards: a foundation grant for non-hormonal contraceptive development and an ARPA-H Sprint award for HPV treatment to prevent cervical cancer.

The panel will discuss the value proposition for investing in women’s health.

J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing visibility around women’s health.

SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced today that Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will be speaking on the ARPA-H | Investing in Women’s Health panel during the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The panel will be on Tuesday, January 14^th at 2:15 p.m. PT and will be followed by two additional panels focused on women’s health, The Future of Women’s Health Care and Flow of Capital to Women’s Health.

“It's very encouraging to see women’s health highlighted so prominently as we kick off the new year; first with our joint ringing of the Nasdaq closing bell in collaboration with the Advanced Research Projects Agency for Health (ARPA-H) on January 2^nd, and now with the Women’s Health Series at the J.P. Morgan conference,” said Ms. Johnson. “We believe that building on last year’s momentum, we can continue to bring women’s health to the forefront of conversation and champion the opportunity for increased investment in women’s health. We believe Daré is well positioned with investigational products in development that are some of the most potentially disruptive therapeutic candidates for women in decades in the areas of contraception, sexual health, menopause, infectious disease, fertility and pelvic pain.”

Ms. Johnson will also be a featured speaker at an event hosted by Grant Engine during the J.P. Morgan conference on Wednesday, January 15^th at 1:55 p.m. PT on Fueling Innovation with Non-Dilutive Funding, where she will highlight the two non-dilutive funding awards Daré was selected in 2024 to receive of approximately $10 million each; a foundation award to support the identification and development of a novel non-hormonal contraceptive candidate, and an ARPA-H Sprint for Women’s Health award to develop an HPV treatment to prevent cervical cancer.

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious diseases, and menopause.

The first FDA-approved product to emerge from Daré’s portfolio of women’s health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ingredient in Viagra®, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Daré’s full portfolio of women’s health product candidates and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In 2023, Daré's CEO was honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré Bioscience placed #1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Forward-Looking Statements

Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to the potential for increased investment in women’s health and Daré’s plans and expectations with respect to its product candidates, including potential for regulatory approval, potential for multiple product candidates, if approved, to be first-in-category products, and the commercial potential of its product candidates, if approved. As used in this press release, the description of a product candidate as “first-in-category” is a forward-looking statement relating to the potential of the candidate to represent a new category of product if it were to receive marketing approval for the indication for which Daré is developing it. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Daré’s ability to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue as a going concern; the inherent uncertainty of outcomes of clinical trials of drug products; Daré’s ability to achieve the product development and other milestones required for it to receive payments under its ARPA-H funding award and grant agreements with the foundation; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate; Daré’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding clinical and/or nonclinical study data; the risk that development of a product candidate requires more clinical and/or nonclinical studies than Daré anticipates; the loss of, or inability to attract, key personnel; the effects of macroeconomic conditions, geopolitical events, public health emergencies, and major disruptions in government operations on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives; the risk that developments by competitors make Daré’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré’s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré’s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré’s product or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cybersecurity incidents or similar events that compromise Daré’s technology systems or those of third parties on which it relies and/or significantly disrupt Daré’s business; and disputes or other developments concerning Daré’s intellectual property rights. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.

FAQ

What panels will be featured at the J.P. Morgan Healthcare Conference's Women's Health Series?

The conference will feature three panels: ARPA-H | Investing in Women's Health, The Future of Women's Health Care, and Flow of Capital to Women's Health.

How much funding did DARE receive in recent non-dilutive awards?

Daré Bioscience received two non-dilutive funding awards of approximately $10 million each in 2024.

What therapeutic areas is DARE currently focusing on in their development pipeline?

Daré is developing therapeutic candidates in contraception, sexual health, menopause, infectious disease, fertility, and pelvic pain.

When and where will Sabrina Martucci Johnson speak at the J.P. Morgan Healthcare Conference?

Johnson will speak on Tuesday, January 14th at 2:15 p.m. PT in San Francisco, CA.

What are the specific purposes of DARE's two $10 million funding awards?

One award is a foundation grant for developing a novel non-hormonal contraceptive, and the other is an ARPA-H Sprint award for developing an HPV treatment to prevent cervical cancer.